Submission of certificate under Regulation 74(5) of SEBI (DP), Regulations, 2018 for the quarter ended 31.03.2025
Awaiting price reaction for this filing.
MPS Pharmaa Limited (formerly Advik Laboratories Limited) has submitted its quarterly investor complaint statement for Q4 FY25 (January to March 2025) to BSE as required under SEBI LODR Regulation 13(3). The report shows zero complaints pending at the start of the quarter, zero received during the quarter, zero disposed of, and zero remaining unresolved at the end of the quarter. The filing was signed by Company Secretary Pooja Chuni on 15 April 2025. This is a standard routine compliance submission confirming that no shareholder grievance was reported or pending during the period.
This is a routine regulatory compliance filing with no material impact on shareholders or the stock price. Zero unresolved complaints indicate clean investor grievance handling for the quarter.